Table 3 Characteristics of patients with CEC following RS or CRT before and after PSM
Characteristic | Before 1:1 PSM (%) | After 1: 1 PSM (%) | |||||
|---|---|---|---|---|---|---|---|
CRT(n = 356) | RS(n = 84) | P value | CRT(n = 80) | RS(n = 80) | P value | ||
Year of diagnosis | 0.033 | 0.870 | |||||
2004–2010 | 187(52.5%) | 54(64.3%) | 49(61.3%) | 51(63.7%) | |||
2011–2015 | 169(47.5%) | 30(35.7%) | 31(38.8%) | 29(36.3%) | |||
Age, years | 1.000 | 0.635 | |||||
< 65 | 170(47.8%) | 40(47.6%) | 41(51.2%) | 37(46.3%) | |||
≥ 65 | 186(52.2%) | 44(52.4%) | 39(48.8%) | 43(53.8%) | |||
Sex | 0.385 | 0.383 | |||||
Male | 213(59.8%) | 55(65.5%) | 60(75.0%) | 54(67.5%) | |||
Female | 143(40.2%) | 29(34.5%) | 20(25.0%) | 26(32.5%) | |||
Race | 0.163 | 0.791 | |||||
White | 271(76.1%) | 70(83.3%) | 65(81.3%) | 68(85.0%) | |||
Black | 59(16.6%) | 7(8.3%) | 8(10.0%) | 7(8.8%) | |||
Other | 26(7.3%) | 7(8.3%) | 7(8.8%) | 5(6.3%) | |||
Tumor grade | 0.060 | 0.646 | |||||
I | 15(4.2%) | 7(8.3%) | 4(5%) | 6(7.5%) | |||
II | 163(45.8%) | 42(50%) | 38(47.5%) | 41(51.2%) | |||
III | 93(26.1%) | 25(29.8%) | 30(37.5%) | 23(28.7%) | |||
Other | 85(23.9%) | 10(11.9%) | 8(10%) | 10(12.5%) | |||
Histology | < 0.001 | 1.000 | |||||
SCC | 336(94.4%) | 69(82.1%) | 69(86.3%) | 69(86.3%) | |||
AD | 19(5.3%) | 11(13.1%) | 10(12.5%) | 10(12.5%) | |||
Other | 1(0.3%) | 4(4.8%) | 1(1.3%) | 1(1.3%) | |||
T stage | 0.902 | 0.349 | |||||
T 1 | 86(24.2%) | 19(22.6%) | 19(23.8%) | 19(23.8%) | |||
T 2 | 33(9.3%) | 10(11.9%) | 13(16.3%) | 9(11.3%) | |||
T 3 | 123(34.6%) | 29(34.5%) | 18(22.5%) | 27(33.8%) | |||
T 4 | 114(32.0%) | 26(31.0%) | 30(37.5%) | 25(31.3%) | |||
N stage | < 0.001 | 1.000 | |||||
N0 | 180(50.6%) | 62(73.8%) | 58(72.5%) | 59(73.8%) | |||
N1 | 176(49.4%) | 22(26.2%) | 22(27.5%) | 21(26.3%) | |||